Skip to content

Research highlight: EGFR mutations in NSCLC

 

This month, the Genetics Journal Club features a double-blind randomized clinical trial which compared the use of a third-generation irreversible EGFR-TKI (osimertinib) versus standard therapy (gefitinib or erlotinib) to treat non small-cell lung cancer.  You can read the results of this study in the New England Journal of Medicine.

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., ... & Okamoto, I. (2017). Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine.

To learn more about EGFR mutations in non small-cell lung cancer, explore additional readings from Himmelfarb Library's full-text collection:

Explore more of Himmelfarb Library's genetics collection by checking out:

Leave a Reply

Your email address will not be published. Required fields are marked *

GW is committed to digital accessibility. If you experience a barrier that affects your ability to access content on this page, let us know via the Accessibility Feedback Form.